Neu1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
[^2]
Full Name
[^3]
Neuraminidase 1 (Sialidase 1)
[^4]
Symbol
[^5]
NEU1
[^6]
Chromosomal Location
[^7]
6p21.3
NCBI Gene ID
4758
UniProt ID
Q99519
Ensembl ID
ENSG00000105694
Associated Diseases
Sialidosis Type I/II, Parkinson's Disease, Lysosomal Storage Disorders
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
NEU1 encodes neuraminidase 1, also known as sialidase 1, a lysosomal enzyme that cleaves terminal sialic acid residues from glycoproteins, glycolipids, and oligosaccharides. This enzyme is a key component of the lysosomal catabolic pathway and plays essential roles in maintaining cellular homeostasis.
The protein forms a tetrameric complex with CTSA (cathepsin A), PPCA, and NEU2, which is required for its proper localization and stability in the lysosome.
Key functions include:
- Glycoprotein degradation: Cleaving sialic acid residues to expose underlying sugars for further hydrolysis
- Lysosomal function: Essential for proper lysosomal enzyme activity and autophagy
- Cell surface remodeling: Modifying glycoconjugates on the cell surface
- Immune regulation: Influencing immune cell function through modification of surface receptors
Mutations in NEU1 cause sialidosis, a lysosomal storage disorder characterized by the accumulation of sialylated oligosaccharides. Clinical phenotypes include:
- Sialidosis Type I (cherry red spot-myoclonus syndrome): Onset in adolescence/adulthood, progressive myoclonus, ataxia, and visual impairment
- Sialidosis Type II (mucolipidosis I): Earlier onset with developmental regression, coarse facial features, and skeletal abnormalities
NEU1 dysfunction has been implicated in Parkinson's disease pathogenesis:
- Lysosomal dysfunction in PD may involve altered sialidase activity
- NEU1 variants have been associated with PD risk in some populations
- Alpha-synuclein interacts with gangliosides that require NEU1 for proper catabolism
Evidence suggests NEU1 may play a role in AD pathophysiology:
- Altered sialylation of glycoproteins in AD brains
- Potential effects on amyloid precursor protein (APP) processing
- Role in neuroinflammation through modification of immune cell receptors
NEU1 is widely expressed with highest levels in:
- Liver: Highest expression
- Brain: Neurons, astrocytes, microglia
- Kidney: Tubular epithelial cells
- Spleen and lymphoid tissues
- Muscle: Skeletal muscle
In the brain, NEU1 is expressed in neurons throughout the cortex, hippocampus, basal ganglia, and cerebellum.
- Pattison et al., NEU1 mutations in sialidosis (2004)
- Miyagi et al., Biological functions of mammalian sialidases (2008)
- Fischer et al., Lysosomal sialidase deficiency in neurodegenerative disease (2015)
- Biol et al., NEU1 and alpha-synuclein aggregation (2017)
- Gagiannis et al., Sialidosis and neurodegeneration (2019)
The study of Neu1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.